Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot in acromegaly patients

Camurus AB Sweden

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC)Increased biochemical response rates (IGF-1?1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom and quality of life scores vs baselineStudy results reinforce previously reported interim results from ACROINNOVA 21View original content:https://www.prnewswire.co.uk/news-releases/camurus-announces-positive-phase-3-results-from-the-acroinnova-2-study-of-octreotide-sc-depot-cam2029-in-acromegaly-patients-302196596.html